articleTop 1% cited

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

The Lancet Oncology · 2018 · Vol. 20(1) · pp. 31–42

Frederick L. Locke✉(Moffitt Cancer Center)Armin Ghobadi(Washington University in St. Louis)Caron A. Jacobson(Dana-Farber Cancer Institute)David B. Miklos(Stanford University)Lazaros J. Lekakis(University of Miami Health System)Olalekan O. Oluwole(Vanderbilt University)Yi Lin(Mayo Clinic in Arizona)Ira Braunschweig(Montefiore Medical Center)Brian T. Hill(Cleveland Clinic)John M. Timmerman(University of California, Los Angeles)Abhinav Deol(Wayne State University)Patrick M. Reagan(University of Rochester Medical Center)Patrick J. Stiff(Loyola University Chicago)Ian W. Flinn(Sarah Cannon)Umar Farooq(University of Iowa)André Goy(Hackensack University Medical Center)Peter A. McSweeney(Colorado Blood Cancer Institute)Javier Muñoz(The University of Texas MD Anderson Cancer Center)Tanya Siddiqi(City Of Hope National Medical Center)Julio C. Chávez(Moffitt Cancer Center)Alex F. Herrera(City Of Hope National Medical Center)Nancy L. Bartlett(Washington University in St. Louis)Jeffrey S. Wiezorek(Kite (United States))Lynn Navale(Kite (United States))Allen Xue(Kite (United States))Yizhou Jiang(Kite (United States))Adrian Bot(Kite (United States))John M. Rossi(Kite (United States))Jaeyeon Kim(Kite (United States))William Y. Go(Kite (United States))Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center)

View via DOI Publisher page

CAR-T cell therapy research Immune Cell Function and Interaction Virus-based gene therapy researchMedicineRefractory (planetary science)OncologyLymphomaInternal medicineMaterials science

MeSH terms

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiological ProductsCyclophosphamideFemaleFollow-Up StudiesHumansLymphoma, FollicularMaleMiddle AgedVidarabineSurvival AnalysisImmunotherapy, AdoptiveLymphoma, Large B-Cell, Diffuse